IP Library › Granted Patent US 11,629,192
Granted Patent B2
US 11,629,192 · App. 16/120,514 · Granted Apr 18, 2023

Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway

Inventors: Zakia Belaid-Choucair (Paris, FR); Olivier Hermine (Paris, FR); Carmen Garrido-Fleury (Dijon, FR); Claude Cochet (Grenoble, FR); Odile Filhol-Cochet (Grenoble, FR); Renaud Seigneuric (Dijon, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITÉ PARIS CITÉ; FONDATION IMAGINE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE GRENOBLE ALPES; COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES; UNIVERSITE DE BOURGOGNE
C07K16/2863A61K31/4745A61K31/713A61K31/7105A61K38/17A61K39/39558A61K45/06C12N15/1138G01N33/566C07K2317/76C12N2310/14C12N2310/531C12N2320/31G01N2333/70503G01N2333/71G01N2500/02Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,629,192
App. No.
16/120,514
Granted
Apr 18, 2023
Kind
B2
Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Claims (8)

1. A method for treating a cancer having cells that express neuropilin-1 (NRP-1)/OBR complex in a subject in need thereof comprising

determining that the cancer has cells expressing the NRP-1/OBR complex; and

administering to the subject a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway, wherein the antagonist of the NRP-1/OBR signaling pathway is a CK2 inhibitor such that the CK2 inhibitor inhibits transport of the NRP-1/OBR complex to the nucleus of the cells expressing the NRP-1/OBR complex.

2. The method of claim 1 wherein the CK2 inhibitor is an allosteric CK2 inhibitor.

3. The method of claim 1 wherein the antagonist of the NRP-1/OBR signaling pathway is combined with an anti-VEGF agent.

4. A method for treating a cancer in a subject in need thereof comprising

determining that the cancer has cells expressing NRP-1/OBR complex; and

administering to the subject a therapeutically effective amount of an anti-VEGF agent and a therapeutically effective amount of a CK2 inhibitor such that the CK2 inhibitor inhibits transport of the NRP-1/OBR complex to the nucleus of the cells expressing the NRP-1/OBR complex.

Assignments (3)
CHANGE OF NAME Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER Recorded Jul 22, 2021
From: UNIVERSITE DE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 056958/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2018
From: BELAID-CHOUCAIR, ZAKIA; HERMINE, OLIVIER; GARRIDO-FLEURY, CARMEN; COCHET, CLAUDE; FILHOL-COCHET, ODILE; SEIGNEURIC, RENAUD
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; FONDATION IMAGINE; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE GRENOBLE ALPES; COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES; UNIVERSITE DE BOURGOGNE
Reel/Frame 046775/0723 →
Priority Claims (1)
EP 14305220 · Feb 18, 2014 · regional
Continuity (2)
Division 15119401
Related Publication 20190002569A1 · Jan 3, 2019